What is the share price of Parnax Lab Ltd (PARNAXLAB) today?
The share price of PARNAXLAB as on 7th July 2025 is ₹105.55. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Parnax Lab Ltd (PARNAXLAB) share?
The past returns of Parnax Lab Ltd (PARNAXLAB) share are- Past 1 week: -1.26%
- Past 1 month: -6.79%
- Past 3 months: -0.66%
- Past 6 months: -33.59%
- Past 1 year: 4.62%
- Past 3 years: 20.62%
- Past 5 years: 538.18%
What are the peers or stocks similar to Parnax Lab Ltd (PARNAXLAB)?
The peers or stocks similar to Parnax Lab Ltd (PARNAXLAB) include:What is the market cap of Parnax Lab Ltd (PARNAXLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Parnax Lab Ltd (PARNAXLAB) is ₹120.94 Cr as of 7th July 2025.What is the 52 week high and low of Parnax Lab Ltd (PARNAXLAB) share?
The 52-week high of Parnax Lab Ltd (PARNAXLAB) is ₹193.50 and the 52-week low is ₹81.What is the PE and PB ratio of Parnax Lab Ltd (PARNAXLAB) stock?
The P/E (price-to-earnings) ratio of Parnax Lab Ltd (PARNAXLAB) is 10.51. The P/B (price-to-book) ratio is 1.69.Which sector does Parnax Lab Ltd (PARNAXLAB) belong to?
Parnax Lab Ltd (PARNAXLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Parnax Lab Ltd (PARNAXLAB) shares?
You can directly buy Parnax Lab Ltd (PARNAXLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Parnax Lab Ltd
PARNAXLAB Share Price
105.553.28% (+3.35)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PARNAXLAB Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PARNAXLAB Performance & Key Metrics
PARNAXLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 10.53 | 1.69 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.97 | 6.46 | 0.64% |
PARNAXLAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PARNAXLAB Company Profile
Parnax Lab is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations
SUNPHARMA
PE Ratio
36.88
36.88
1Y Return
7.93%
7.93%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.14
23.14
1Y Return
1.58%
1.58%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
59.36
59.36
1Y Return
16.29%
16.29%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
19.28
19.28
1Y Return
0.28%
0.28%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
22.21
22.21
1Y Return
13.73%
13.73%
Buy Reco %
44.44
44.44
PARNAXLAB Forecast
PARNAXLAB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PARNAXLAB
PARNAXLAB
Income
Balance Sheet
Cash Flow
Annual Normal View
PARNAXLAB Income Statement
PARNAXLAB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 95.18 | 106.69 | 110.89 | 95.97 | 90.27 | 163.36 | 168.38 | 189.53 | 189.41 | 189.41 | ||||||||||
Raw Materials | 58.02 | 62.23 | 59.93 | 54.43 | 48.49 | 101.47 | 101.31 | 118.31 | 160.97 | 160.97 | ||||||||||
| Power & Fuel Cost | 3.27 | 2.99 | 3.13 | 4.12 | 4.29 | 5.24 | 5.37 | 6.37 | ||||||||||||
| Employee Cost | 9.22 | 11.68 | 13.06 | 14.08 | 13.68 | 17.43 | 20.05 | 23.72 | ||||||||||||
| Selling & Administrative Expenses | 4.49 | 8.09 | 12.36 | 6.74 | 4.86 | 6.75 | 8.33 | 8.54 | ||||||||||||
| Operating & Other expenses | 6.79 | 10.61 | 10.08 | 9.51 | 8.80 | 9.11 | 9.56 | 8.23 | ||||||||||||
EBITDA | 13.39 | 11.09 | 12.33 | 7.09 | 10.15 | 23.36 | 23.76 | 24.36 | 28.44 | 28.44 | ||||||||||
| Depreciation/Amortization | 3.75 | 3.74 | 3.82 | 4.46 | 5.16 | 5.87 | 6.53 | 6.96 | 7.38 | 7.39 | ||||||||||
| PBIT | 9.64 | 7.35 | 8.51 | 2.63 | 4.99 | 17.49 | 17.23 | 17.40 | 21.06 | 21.05 | ||||||||||
| Interest & Other Items | 4.92 | 4.32 | 3.89 | 4.60 | 5.08 | 5.23 | 4.95 | 5.35 | 5.39 | 5.39 | ||||||||||
| PBT | 4.72 | 3.03 | 4.62 | -1.97 | -0.09 | 12.26 | 12.28 | 12.05 | 15.67 | 15.66 | ||||||||||
| Taxes & Other Items | 1.03 | 1.97 | 1.32 | 0.95 | 0.28 | 4.03 | 3.66 | 2.44 | 4.16 | 4.17 | ||||||||||
| Net Income | 3.69 | 1.06 | 3.30 | -2.92 | -0.37 | 8.23 | 8.62 | 9.61 | 11.51 | 11.49 | ||||||||||
| EPS | 4.34 | 1.25 | 3.88 | -3.43 | -0.44 | 8.98 | 8.09 | 8.37 | 10.05 | 10.00 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PARNAXLAB Company Updates
PARNAXLAB Stock Peers
PARNAXLAB Past Performance & Peer Comparison
PARNAXLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Parnax Lab Ltd | 10.51 | 1.69 | — |
| Sun Pharmaceutical Industries Ltd | 36.88 | 5.56 | — |
| Cipla Ltd | 23.14 | 3.90 | 1.06% |
| Torrent Pharmaceuticals Ltd | 59.36 | 14.95 | — |
PARNAXLAB Stock Price Comparison
Compare PARNAXLAB with any stock or ETFCompare PARNAXLAB with any stock or ETF
PARNAXLAB
PARNAXLAB Holdings
PARNAXLAB Shareholdings
PARNAXLAB Promoter Holdings Trend
PARNAXLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
PARNAXLAB Institutional Holdings Trend
PARNAXLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PARNAXLAB Shareholding Pattern
PARNAXLAB Shareholding Pattern
PARNAXLAB Shareholding History
PARNAXLAB Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PARNAXLAB stock
smallcases containing PARNAXLAB stock
Looks like this stock is not in any smallcase yet.
PARNAXLAB Events
PARNAXLAB Events
PARNAXLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PARNAXLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PARNAXLAB Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
PARNAXLAB has not given any dividends in last 5 years
PARNAXLAB Dividends
PARNAXLAB Dividends
Hmm, looks like data is unavailable here. Please come back after some timePARNAXLAB Stock News & Opinions
PARNAXLAB Stock News & Opinions
Articles & Videos
Earnings
Parnax Lab consolidated net profit rises 30.36% in the March 2025 quarter
Net profit of Parnax Lab rose 30.36% to Rs 2.92 crore in the quarter ended March 2025 as against Rs 2.24 crore during the previous quarter ended March 2024. Sales rose 5.76% to Rs 49.04 crore in the quarter ended March 2025 as against Rs 46.37 crore during the previous quarter ended March 2024. For the full year,net profit rose 19.88% to Rs 11.52 crore in the year ended March 2025 as against Rs 9.61 crore during the previous year ended March 2024. Sales declined 0.51% to Rs 187.74 crore in the year ended March 2025 as against Rs 188.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales49.0446.37 6 187.74188.71 -1 OPM %13.5212.49 -14.2512.47 - PBDT5.784.63 25 23.0519.01 21 PBT3.952.79 42 15.6712.05 30 NP2.922.24 30 11.529.61 20 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Parnax Lab to discuss results
Parnax Lab will hold a meeting of the Board of Directors of the Company on 27 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Parnax Lab consolidated net profit declines 44.50% in the December 2024 quarter
Net profit of Parnax Lab declined 44.50% to Rs 1.21 crore in the quarter ended December 2024 as against Rs 2.18 crore during the previous quarter ended December 2023. Sales declined 21.12% to Rs 40.22 crore in the quarter ended December 2024 as against Rs 50.99 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales40.2250.99 -21 OPM %10.6211.71 - PBDT3.234.72 -32 PBT1.452.94 -51 NP1.212.18 -44 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Parnax Lab to declare Quarterly Results
Parnax Lab will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Parnax Lab consolidated net profit rises 82.35% in the September 2024 quarter
Net profit of Parnax Lab rose 82.35% to Rs 3.41 crore in the quarter ended September 2024 as against Rs 1.87 crore during the previous quarter ended September 2023. Sales rose 13.49% to Rs 48.36 crore in the quarter ended September 2024 as against Rs 42.61 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales48.3642.61 13 OPM %14.9712.41 - PBDT6.814.08 67 PBT4.872.34 108 NP3.411.87 82 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Parnax Lab to convene board meeting
Parnax Lab will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Parnax Lab to conduct AGM
Parnax Lab announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Parnax Lab consolidated net profit rises 19.88% in the June 2024 quarter
Net profit of Parnax Lab rose 19.88% to Rs 3.98 crore in the quarter ended June 2024 as against Rs 3.32 crore during the previous quarter ended June 2023. Sales rose 2.83% to Rs 50.12 crore in the quarter ended June 2024 as against Rs 48.74 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales50.1248.74 3 OPM %17.2013.34 - PBDT7.235.58 30 PBT5.403.98 36 NP3.983.32 20 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Parnax Lab announces board meeting date
Parnax Lab will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Parnax Lab Consolidated March 2023 Net Sales at Rs 40.91 crore, down 14.62% Y-o-Y
2 years agoMoneycontrol
Over the last 5 years, revenue has grown at a yearly rate of 14.57%, vs industry avg of 10.22%
Over the last 5 years, market share increased from 0.04% to 0.05%